Xylem and Partners Volunteer 157,000 Hours Toward Solving Water and Sustainability Challenges in 2022
20.2.2023 17:00:00 EET | Business Wire | Press release
Global water technology leader, Xylem (NYSE: XYL), reports that 87% of employees volunteered time in 2022, combining their efforts with volunteers from Xylem’s customers and partners around the world. The employee volunteers dedicated 157,000 hours during the year, an increase of 39% from 2021.
More than 15,600 employees participated in Xylem’s corporate social responsibility program, Xylem Watermark, in 2022, supporting a range of initiatives such as educating the next generation about critical water challenges, expanding access to safe water and sanitation, and supporting communities in crisis.
“Xylem Watermark is fundamental to our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our employees and partners showed remarkable commitment to solving short- and long-term water challenges in 2022, with 160 offices having 100% employee participation. We are proud of our teams and partners, who have already begun 2023 by volunteering in response to community needs, everywhere, including support for relief efforts and provision of fresh water to earthquake-affected regions of Turkey.”
“In 2022, our partnership with Xylem delivered clean water and sanitation to more than 2 million people affected by poverty or disaster,” said Rose Hogan, Interim Technical Unit Vice President at Americares. “Through the continued commitment of the Xylem team, we’ve provided water, sanitation, and hygiene education in India and Bangladesh, including infrastructure improvements and critical repairs in 27 health centers and six schools. We are incredibly proud of what we’ve achieved together in 2022.”
Employee’s volunteer efforts also contribute to Xylem’s 2025 Sustainability Goals, which include: providing access to clean water and sanitation for at least 20 million people; providing water and WASH (Water and Sanitation Hygiene) education for 15 million people; and giving 1% of profits and 1% of employee time to water-related causes and education.
In 2022, Xylem Watermark projects included:
- To support relief efforts in Ukraine, Xylem employees raised funds, hosted refugee families, collected supplies, donated equipment, and deployed emergency water treatment systems that serve 128,000 people.
- Xylem’s Humanitarian Disaster Response Team provided emergency water treatment systems in Ukraine, South Africa, Pakistan, and the Philippines.
- Employees raised water scarcity awareness and reduced water pollution through the global “Take Steps to Solve Water” campaign, featuring Manchester City manager Pep Guardiola.
- Partnering with NGO organizations including Americares, Engineers Without Borders, and Planet Water Foundation, Xylem Watermark supported the expansion of safe water and sanitation access to schools, hospitals, and communities, reaching 2.4 million people.
- Xylem Ignite continued to inspire future water leaders, with more than 1,200 students participating in the second annual Global Student Innovation Challenge and the Re-New Our World Challenge in the Middle East.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
About Xylem Watermark
Xylem Watermark, the Company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources around the world and also educating people on water-related issues. The global initiative, which encompasses employee and stakeholder engagement, provides access to clean drinking water and sanitation, and humanitarian emergency response to help communities become more water-secure and sustainable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005154/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
